NCT04192617View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate

PHASE2CompletedINTERVENTIONAL

Enrollment

156

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 3, 2016

Study Completion Date

February 3, 2016

Conditions

Rheumatoid Arthritis

Interventions

DRUG

SM03

SM03: 600 mg intravenous (IV)

DRUG

Placebo

Placebo: 600 mg intravenous (IV)

DRUG

Methotrexate

methotrexate: 7.5-20 mg/week oral

Trial Locations (1)

100032

Peking Union Medical College Hostipal, Beijing

All Listed Sponsors

lead

SinoMab BioScience Ltd

INDUSTRY

NCT04192617 - A Study to Evaluate the Safety and Efficacy of SM03 in Patients With Rheumatoid Arthritis Receiving Methotrexate | Biotech Hunter | Biotech Hunter